QPPV.COM KNOWLEDGE ASSESSMENT

Ustekinumab Biosimilars: IL-12/23 Biology, Interchangeability and Product Pharmacovigilance

Test your understanding of the concepts covered by Ustekinumab Biosimilars: IL-12/23 Biology, Interchangeability and Product Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A report mentions headache and 'possible posterior reversible encephalopathy syndrome' but contains no neurological examination or imaging information. What is the best assessment approach?

Confirm the syndrome based on headache alone Reject the report because rare neurological events are not relevant Seek syndrome-level clinical and imaging evidence before interpreting it as that condition Treat every headache after ustekinumab as a serious neurological signal

Question 2 of 10 Which factor is least appropriate to treat as evidence that a switch caused an adverse event?

The event occurred after the first dose of the new product The patient had a documented dosing delay during the switch The patient developed relevant anti-drug antibodies supported by appropriate testing The event followed a change in device or administration process

Question 3 of 10 Which information is most useful when evaluating a report of worsening arthritis after a prefilled syringe leaked during administration?

Only the patient's age and country The amount delivered, device condition, lot number, storage, injection training and subsequent disease course Only whether the product was a biosimilar The patient's history of unrelated respiratory infections

Question 4 of 10 Why does biosimilar development place substantial emphasis on analytical and functional comparison before clinical studies?

Clinical trials cannot assess safety or efficacy under any circumstances High-resolution analytical methods are more sensitive than clinical outcomes for detecting subtle structural or functional differences Analytical studies are used to replace all immunogenicity assessment Regulators require analytical testing only for small-molecule medicines

Question 5 of 10 Which report best illustrates a medication error requiring specific product and administration follow-up?

A patient reports mild fatigue with no treatment details A patient receives a subcutaneous maintenance syringe in place of the intended intravenous induction regimen A patient has stable disease after a correctly administered dose A patient reports a headache without timing or clinical findings

Question 6 of 10 Which distinction is particularly important when evaluating injection-related reports?

Local injection-site reactions should be distinguished from systemic hypersensitivity All injection-site pain should be classified as anaphylaxis Device leakage always demonstrates altered antibody potency Systemic hypersensitivity can be assessed without considering onset after dosing

Question 7 of 10 What is the most accurate interpretation of Wezenla's EU regulatory position?

It has an EU-wide FDA-style statutory interchangeability designation It is authorised as a biosimilar, while interchangeability and pharmacy-level substitution are handled within national frameworks It is treated as a generic because all biologics are legally identical to their references It cannot be used for any indication previously authorised for the reference product

Question 8 of 10 Why may a biosimilar receive authorisation for additional reference-product indications without a separate full efficacy trial in each disease?

Because all immune-mediated diseases are considered interchangeable clinical conditions Because the totality of similarity evidence and the established mechanism may support scientific extrapolation Because biosimilars are exempt from indication-specific regulatory review Because efficacy is not relevant once a product is shown to be injectable

Question 9 of 10 What is the most appropriate role of immunogenicity data in a switch-related case?

Assume anti-drug antibodies whenever symptoms follow a switch Consider anti-drug antibodies when clinically obtained and interpreted with exposure, timing and disease-course information Use a temporal switch relationship as a substitute for antibody testing Ignore immunogenicity because all monoclonal antibodies are fully human

Question 10 of 10 Why must intravenous and subcutaneous ustekinumab presentations be distinguished in medication-safety assessment?

They contain different active substances They have different administration routes, uses and error modes despite containing ustekinumab The subcutaneous presentation is not a biological medicine The intravenous presentation is used only for psoriasis

QPPV.com

Ustekinumab Biosimilars: IL-12/23 Biology, Interchangeability and Product Pharmacovigilance

Cookie Settings